![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TMEM167A |
Gene summary for TMEM167A |
![]() |
Gene information | Species | Human | Gene symbol | TMEM167A | Gene ID | 153339 |
Gene name | transmembrane protein 167A | |
Gene Alias | TMEM167 | |
Cytomap | 5q14.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8TBQ9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
153339 | TMEM167A | GSM4909281 | Human | Breast | IDC | 1.53e-04 | 3.64e-01 | 0.21 |
153339 | TMEM167A | GSM4909285 | Human | Breast | IDC | 5.72e-29 | 6.45e-01 | 0.21 |
153339 | TMEM167A | GSM4909290 | Human | Breast | IDC | 2.94e-07 | 4.67e-01 | 0.2096 |
153339 | TMEM167A | GSM4909293 | Human | Breast | IDC | 9.60e-08 | 3.75e-01 | 0.1581 |
153339 | TMEM167A | GSM4909296 | Human | Breast | IDC | 4.26e-05 | 1.08e-02 | 0.1524 |
153339 | TMEM167A | GSM4909297 | Human | Breast | IDC | 2.20e-10 | -1.67e-01 | 0.1517 |
153339 | TMEM167A | GSM4909308 | Human | Breast | IDC | 2.21e-08 | 4.08e-01 | 0.158 |
153339 | TMEM167A | GSM4909311 | Human | Breast | IDC | 3.80e-22 | -2.52e-01 | 0.1534 |
153339 | TMEM167A | GSM4909312 | Human | Breast | IDC | 5.22e-09 | 1.14e-03 | 0.1552 |
153339 | TMEM167A | GSM4909315 | Human | Breast | IDC | 6.70e-03 | 3.15e-01 | 0.21 |
153339 | TMEM167A | GSM4909319 | Human | Breast | IDC | 1.10e-24 | -2.20e-01 | 0.1563 |
153339 | TMEM167A | GSM4909320 | Human | Breast | IDC | 2.37e-03 | -1.69e-01 | 0.1575 |
153339 | TMEM167A | GSM4909321 | Human | Breast | IDC | 1.06e-07 | 5.62e-03 | 0.1559 |
153339 | TMEM167A | brca2 | Human | Breast | Precancer | 5.42e-04 | 2.62e-01 | -0.024 |
153339 | TMEM167A | NCCBC14 | Human | Breast | DCIS | 2.80e-03 | -1.14e-01 | 0.2021 |
153339 | TMEM167A | NCCBC5 | Human | Breast | DCIS | 2.67e-03 | -1.33e-02 | 0.2046 |
153339 | TMEM167A | P1 | Human | Breast | IDC | 2.22e-07 | -1.47e-01 | 0.1527 |
153339 | TMEM167A | P3 | Human | Breast | IDC | 2.00e-10 | 7.68e-01 | 0.1542 |
153339 | TMEM167A | DCIS2 | Human | Breast | DCIS | 7.05e-54 | 1.31e-01 | 0.0085 |
153339 | TMEM167A | AEH-subject1 | Human | Endometrium | AEH | 3.13e-04 | -2.29e-01 | -0.3059 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000930610 | Oral cavity | OSCC | protein secretion | 169/7305 | 359/18723 | 1.04e-03 | 5.34e-03 | 169 |
GO:003559210 | Oral cavity | OSCC | establishment of protein localization to extracellular region | 169/7305 | 360/18723 | 1.21e-03 | 6.08e-03 | 169 |
GO:00716929 | Oral cavity | OSCC | protein localization to extracellular region | 172/7305 | 368/18723 | 1.40e-03 | 6.79e-03 | 172 |
GO:007169216 | Thyroid | PTC | protein localization to extracellular region | 139/5968 | 368/18723 | 8.95e-03 | 3.72e-02 | 139 |
GO:000930618 | Thyroid | PTC | protein secretion | 135/5968 | 359/18723 | 1.16e-02 | 4.58e-02 | 135 |
GO:003559218 | Thyroid | PTC | establishment of protein localization to extracellular region | 135/5968 | 360/18723 | 1.28e-02 | 4.95e-02 | 135 |
GO:007169223 | Thyroid | ATC | protein localization to extracellular region | 150/6293 | 368/18723 | 2.25e-03 | 1.05e-02 | 150 |
GO:000930623 | Thyroid | ATC | protein secretion | 146/6293 | 359/18723 | 2.83e-03 | 1.29e-02 | 146 |
GO:003559223 | Thyroid | ATC | establishment of protein localization to extracellular region | 146/6293 | 360/18723 | 3.20e-03 | 1.44e-02 | 146 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM167A | SNV | Missense_Mutation | c.175G>A | p.Val59Ile | p.V59I | Q8TBQ9 | protein_coding | tolerated(0.76) | benign(0) | TCGA-BH-A0E1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
TMEM167A | SNV | Missense_Mutation | c.33N>C | p.Leu11Phe | p.L11F | Q8TBQ9 | protein_coding | deleterious(0.03) | probably_damaging(0.991) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
TMEM167A | SNV | Missense_Mutation | c.143N>A | p.Arg48Lys | p.R48K | Q8TBQ9 | protein_coding | tolerated(0.06) | benign(0.358) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
TMEM167A | SNV | Missense_Mutation | c.187G>C | p.Val63Leu | p.V63L | Q8TBQ9 | protein_coding | tolerated(0.33) | benign(0) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
TMEM167A | SNV | Missense_Mutation | novel | c.18N>G | p.Asn6Lys | p.N6K | Q8TBQ9 | protein_coding | deleterious(0.04) | possibly_damaging(0.703) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
TMEM167A | SNV | Missense_Mutation | novel | c.34N>T | p.Thr12Ser | p.T12S | Q8TBQ9 | protein_coding | tolerated(0.25) | benign(0.007) | TCGA-DM-A282-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM167A | SNV | Missense_Mutation | c.143N>T | p.Arg48Ile | p.R48I | Q8TBQ9 | protein_coding | tolerated(0.05) | benign(0.105) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TMEM167A | SNV | Missense_Mutation | novel | c.92N>C | p.Leu31Pro | p.L31P | Q8TBQ9 | protein_coding | deleterious(0) | possibly_damaging(0.908) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
TMEM167A | SNV | Missense_Mutation | rs868081483 | c.139N>T | p.Ala47Ser | p.A47S | Q8TBQ9 | protein_coding | tolerated(0.14) | benign(0.034) | TCGA-SL-A6J9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMEM167A | SNV | Missense_Mutation | novel | c.214N>A | p.Gln72Lys | p.Q72K | Q8TBQ9 | protein_coding | tolerated(0.09) | benign(0.012) | TCGA-NC-A5HN-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
153339 | TMEM167A | NA | fluorouracil | FLUOROURACIL | 28796378 | |
153339 | TMEM167A | NA | radiotherapy | 28796378 | ||
153339 | TMEM167A | NA | Platinum compounds | 28796378 |
Page: 1 |